ReviewValue in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research2012
A review of generic preference-based measures of health-related quality of life in visual disorders.
Review in Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 9 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 9 syntheses or guidelines pooled it.
- A Systematic Review of Patient-Reported Outcome Instruments Relevant to Glaucoma.Journal of glaucoma · 2026Pooled it
- The management of neovascular age-related macular degeneration: A systematic literature review of patient-reported outcomes, patient mental health and caregiver burden.Acta ophthalmologica · 2023Pooled it
- A systematic review of utility values in children with cerebral palsy.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2019Pooled it
- Assessment of the construct validity and responsiveness of preference-based quality of life measures in people with Parkinson's: a systematic review.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2017Pooled it
- How does age-related macular degeneration affect real-world visual ability and quality of life? A systematic review.BMJ open · 2016Pooled it
- Pooled it
- EQ-5D in skin conditions: an assessment of validity and responsiveness.The European journal of health economics : HEPAC : health economics in prevention and care · 2015Pooled it
- Can The EQ-5D Detect Meaningful Change? A Systematic Review.PharmacoEconomics · 2015Pooled it
- Health state utilities in patients with diabetic retinopathy, diabetic macular oedema and age-related macular degeneration: a systematic review.BMC ophthalmology · 2013Pooled it
- EQ-5D vision bolt-on in macular degeneration: associations with visual measures and effect on utility differences and cost-effectiveness of stereotactic radiotherapy.Health and quality of life outcomes · 2026Trial
- Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT.Health technology assessment (Winchester, England) · 2021Trial
- Mapping From Visual Acuity to EQ-5D, EQ-5D With Vision Bolt-On, and VFQ-UI in Patients With Macular Edema in the LEAVO Trial.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2020Trial
- Treatment of Advanced Glaucoma Study: a multicentre randomised controlled trial comparing primary medical treatment with primary trabeculectomy for people with newly diagnosed advanced glaucoma-study protocol.The British journal of ophthalmology · 2018Trial
- Portable electronic vision enhancement systems in comparison with optical magnifiers for near vision activities: an economic evaluation alongside a randomized crossover trial.Acta ophthalmologica · 2017Trial
- An exploratory study to test the impact on three "bolt-on" items to the EQ-5D.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2015Trial
- Modeling Oxygen Saturation Targets, Mortality, and Retinopathy Among Extremely Preterm Infants.JAMA network open · 2026Article
- X-Linked Retinitis Pigmentosa (XLRP): An Investigation of the Impact of XLRP on Health-Related Quality of Life of Carers in Great Britain.Advances in therapy · 2026Article
- Content Validity of Two Generic Preference-Based Measures in Retinitis Pigmentosa, Including X-Linked Retinitis Pigmentosa.PharmacoEconomics - open · 2026Article
- Health state utilities associated with X-linked retinitis pigmentosa (XLRP).The European journal of health economics : HEPAC : health economics in prevention and care · 2025Article
- Leber hereditary optic neuropathy: utilities and carer burden from British and Irish participants.Orphanet journal of rare diseases · 2025Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveThis review examines generic preference-based measures and their ability to reflect health-related quality of life in patients with visual disorders.
methodsA systematic search was undertaken to identify clinical studies of patients with visual disorders where health state utility values were measured and reported. Data were extracted to assess the validity and responsiveness of the measures. A narrative synthesis of the data was undertaken due to the heterogeneity between different studies.
resultsThere was considerable heterogeneity in the 31 studies identified in terms of patient characteristics, visual disorders, and outcomes reported. Vision loss was associated with a reduction in scores across the preference-based measure, but the evidence on validity and responsiveness was mixed. The EQ-5D health-related assessment instrument's performance differed according to condition, with poor performance in age-related macular degeneration (AMD) and diabetic retinopathy. The more limited evidence on the HUI-3 instrument found it performed best in differentiating between severity groups of patients with glaucoma, AMD, cataracts, and diabetic retinopathy. One study reported data on the SF-6D instrument and showed it was able to differentiate between patients with AMD.
conclusionsThe performance of the EQ-5D in visual disorders was mixed. The HUI-3 seemed to perform better in some conditions, but the evidence on this and SF-6D is limited. More head to head comparisons of these three measures are required. The new five-level version of EQ-5D may do better at the milder end of visual function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.